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Background: The aim of MAPA study was to better understand atherosclerosis and restenosis in peripheral vascular disease. Of a particular 
interest was the superficial femoral artery given that it is the most prominent location for intervention with a high rate of unresolved complications 
and recurring stenosis. In sharp contrast to the remarkable advancement obtained in the treatment of coronary atherosclerosis, the treatment of 
PAD has not yielded comparable success. Moreover drug-eluting stents (DES) which reduced restenosis in coronary arteries down to nominal single 
digits have not demonstrated comparable success in the treatment of SFA
Methods: In order to gain an understanding for the biology of restenosis in SFA lesions we obtained pertinent restenosis specimens from 
atherectomy procedures and compared them with samples from de-novo lesions and with non-diseased SFA specimens for the expression of genes 
that mark inflammation, proliferation, and ECM. In addition, obtaining samples from SFA arteries allowed us to generate SFA derived-smooth muscle 
cells and to study their response to anti-proliferative drugs that are currently in use with combination devices treating coronary and peripheral 
disease.
Results: The data reveals substantial reduction in expression of selected genes, such as KLF4 and BTG2 in atherosclerotic vs. non-disease SFA 
specimens. Since these genes are regulating the cell cycle and inhibit the proliferation of smooth muscle cells, the data explains the enhanced 
proliferative state of the neointimal smooth muscle cells in diseased SFA. The transcriptional expression of genes that are associated with vascular 
inflammation is also outlined by the MAPA study, substantiating the extensive inflammatory makeup of the restenotic disease in SFA and elucidating 
the causal connection to the observed phenotypic shift in the composition of extracellular matrix and proliferative state revealed in the SFA 
specimens
Conclusions: The results from this study delineated the genes that are persistently up regulated trough the development of atherosclerosis in SFA. 
Moreover, MAPA study revealed specific genes that are associated with the development of restenosis in SFA
